Drug intelligence / Profile preview

Empecid L

Development stage: Unknown
Lead developer: Bayer
Modality: Small Molecules
Administration: Topical

Overview

Empecid L is a topical antifungal cream developed by Bayer. Its active ingredient is Clotrimazole 1%, which belongs to the azole class of antifungal agents. It is primarily indicated for the treatment of vulvar itching with rash due to recurrent vaginal candida, also known as vaginal yeast infection. Clotrimazole works by inhibiting the synthesis of ergosterol, a vital component of fungal cell membranes, leading to increased permeability and leakage of cellular contents, ultimately causing fungal cell death.

Brand names: Empecid L Cream
Other names: clotrimazole

Targets

CYP51A1 (Sterol 14α-demethylase)

Beyond the preview

Go deeper on Empecid L.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Empecid L.

Explore the full profile